Related Experiment Video
Updated: Jul 30, 2026
09:37
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Age-related macular degeneration.
1Henry Wellcome Research Laboratories, Applied Vision Research Centre, Department of Optometry and Visual Science, City University, Northampton Square, London, UK. g.arden@city.ac.uk
The Journal of the British Menopause Society
|June 17, 2006
Summary
Age-related macular degeneration (AMD) is a leading cause of blindness, with increasing incidence suggesting environmental factors. Early detection and combined treatments, including diet, may reduce vision loss.
Area of Science:
- Ophthalmology
- Gerontology
- Medical Research
Background:
- Age-related macular degeneration (AMD) is a primary cause of vision impairment, with rising incidence linked to population aging and potential environmental influences.
- AMD is characterized by retinal deposits (drusen) and impaired choroidal circulation, leading to neovascularization (wet AMD) or retinal atrophy (dry AMD).
- Wet AMD involves leakage from new retinal vessels, causing rapid vision loss and disciform degeneration, while dry AMD results in geographic atrophy due to anoxia.
Purpose of the Study:
- To review the current understanding of age-related macular degeneration (AMD) pathophysiology and emerging treatment strategies.
- To highlight the increasing incidence of AMD and the need for effective interventions.
- To explore the potential of combined therapeutic approaches for managing AMD.
Main Methods:
- Review of existing literature on age-related macular degeneration (AMD).
- Analysis of current and emerging treatment modalities, including laser therapy, photodynamic therapy, and anti-angiogenic drugs.
- Discussion of the role of diet and screening in AMD management.
Main Results:
- Current treatments like laser therapy show uncertain long-term benefits; newer micro-pulse lasers are under investigation.
- Emerging therapies include retinal translocation, photodynamic therapy, and intraocular injections of anti-angiogenic drugs like ranibizumab.
- Dietary interventions and regular screening are crucial components for future AMD management.
Conclusions:
- A combination of dietary control, visual screening, and medical/surgical treatments holds promise for reducing blindness from age-related macular degeneration (AMD).
- Further evaluation of anti-angiogenic drugs and dietary roles is necessary.
- Integrated management strategies are key to mitigating the impact of AMD.
More Related Videos
Related Concept Videos
01:22Photoreceptors and Visual Pathways
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category, whereas...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...